Total Payments
$20,789
2024 Payments
$4,503
Companies
19
Transactions
47
Medicare Patients
937
Medicare Billing
$208,437
Payment Breakdown by Category
Consulting$19,588 (94.2%)
Food & Beverage$765.44 (3.7%)
Travel$340.28 (1.6%)
Education$96.25 (0.5%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $19,588 | 12 | 94.2% |
| Food and Beverage | $765.44 | 31 | 3.7% |
| Travel and Lodging | $340.28 | 3 | 1.6% |
| Education | $96.25 | 1 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $9,834 | 13 | $0 (2024) |
| BARD PERIPHERAL VASCULAR, INC. | $7,311 | 4 | $0 (2019) |
| Amgen Inc. | $2,744 | 2 | $0 (2023) |
| Incyte Corporation | $335.00 | 1 | $0 (2018) |
| Takeda Pharmaceuticals U.S.A., Inc. | $129.10 | 3 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $63.77 | 4 | $0 (2018) |
| Ipsen Biopharmaceuticals, Inc | $59.58 | 3 | $0 (2019) |
| Bayer HealthCare Pharmaceuticals Inc. | $52.90 | 2 | $0 (2022) |
| TESARO, Inc. | $33.12 | 2 | $0 (2018) |
| Celgene Corporation | $31.71 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,503 | 8 | AstraZeneca Pharmaceuticals LP ($4,503) |
| 2023 | $7,635 | 6 | AstraZeneca Pharmaceuticals LP ($4,864) |
| 2022 | $516.58 | 4 | AstraZeneca Pharmaceuticals LP ($467.48) |
| 2020 | $20.00 | 1 | Lilly USA, LLC ($20.00) |
| 2019 | $7,375 | 7 | BARD PERIPHERAL VASCULAR, INC. ($7,311) |
| 2018 | $664.69 | 16 | Incyte Corporation ($335.00) |
| 2017 | $75.37 | 5 | Pharmacyclics LLC, An AbbVie Company ($25.33) |
All Payment Transactions
47 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/23/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $3,082.50 | General |
| 10/04/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Travel and Lodging | In-kind items and services | $179.67 | General |
| Category: Oncology | ||||||
| 10/04/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $78.14 | General |
| Category: Oncology | ||||||
| 10/04/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Travel and Lodging | Cash or cash equivalent | $47.37 | General |
| Category: Oncology | ||||||
| 10/04/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | Cash or cash equivalent | $38.04 | General |
| Category: Oncology | ||||||
| 10/01/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 09/13/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $27.70 | General |
| Category: Oncology | ||||||
| 05/22/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 12/10/2023 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,055.00 | General |
| 11/30/2023 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI, MEKTOVI | Food and Beverage | In-kind items and services | $27.05 | General |
| Category: ONCOLOGY | ||||||
| 08/04/2023 | AstraZeneca Pharmaceuticals LP | IMJUDO (Biological) | Consulting Fee | Cash or cash equivalent | $685.00 | General |
| Category: Oncology | ||||||
| 07/25/2023 | AstraZeneca Pharmaceuticals LP | IMJUDO (Biological) | Consulting Fee | Cash or cash equivalent | $2,123.50 | General |
| Category: Oncology | ||||||
| 07/19/2023 | Amgen Inc. | LUMAKRAS (Drug) | Consulting Fee | Cash or cash equivalent | $2,058.00 | General |
| Category: Oncology | ||||||
| 07/19/2023 | Amgen Inc. | LUMAKRAS (Drug) | Consulting Fee | Cash or cash equivalent | $686.00 | General |
| Category: Oncology | ||||||
| 10/26/2022 | Bayer HealthCare Pharmaceuticals Inc. | Vitrakvi (Drug), Stivarga | Food and Beverage | In-kind items and services | $33.40 | General |
| Category: Oncology | ||||||
| 07/03/2022 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $342.50 | General |
| Category: Oncology | ||||||
| 06/04/2022 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $124.98 | General |
| Category: Oncology | ||||||
| 04/26/2022 | Sirtex Medical Inc | SIR-Spheres Microspheres (Device) | Food and Beverage | Cash or cash equivalent | $15.70 | General |
| Category: Interventional Oncology | ||||||
| 06/25/2020 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Oncology | ||||||
| 09/10/2019 | Bayer HealthCare Pharmaceuticals Inc. | Stivarga (Drug) | Food and Beverage | In-kind items and services | $19.50 | General |
| Category: Oncology | ||||||
| 07/12/2019 | BARD PERIPHERAL VASCULAR, INC. | LUTONIX (Device) | Consulting Fee | Cash or cash equivalent | $3,850.00 | General |
| Category: PERIPHERAL VASCULAR | ||||||
| 07/12/2019 | BARD PERIPHERAL VASCULAR, INC. | LUTONIX (Device) | Travel and Lodging | Cash or cash equivalent | $113.24 | General |
| Category: PERIPHERAL VASCULAR | ||||||
| 07/12/2019 | BARD PERIPHERAL VASCULAR, INC. | LUTONIX (Device) | Food and Beverage | In-kind items and services | $27.50 | General |
| Category: PERIPHERAL VASCULAR | ||||||
| 06/13/2019 | Bard Peripheral Vascular, Inc. | Lutonix DCB (Device) | Consulting Fee | Cash or cash equivalent | $3,320.00 | General |
| Category: Peripheral Vascular | ||||||
| 06/05/2019 | Ipsen Biopharmaceuticals, Inc | SOMATULINE DEPOT (Drug), ONIVYDE | Food and Beverage | In-kind items and services | $20.50 | General |
| Category: Oncology/Endocrinology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 263 | 575 | $223,745 | $49,767 |
| 2022 | 8 | 296 | 725 | $277,718 | $63,994 |
| 2021 | 6 | 224 | 598 | $233,083 | $55,970 |
| 2020 | 7 | 154 | 395 | $159,467 | $38,707 |
Total Patients
937
Total Services
2,293
Medicare Billing
$208,437
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 41 | 160 | $65,760 | $13,987 | 21.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 67 | 173 | $47,921 | $9,783 | 20.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 46 | 115 | $31,395 | $8,429 | 26.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 40 | 46 | $24,012 | $5,630 | 23.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 26 | 38 | $21,166 | $5,072 | 24.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 30 | 30 | $23,130 | $4,788 | 20.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 13 | 13 | $10,361 | $2,078 | 20.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 42 | 170 | $69,870 | $15,431 | 22.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 59 | 221 | $60,333 | $14,779 | 24.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 48 | 51 | $39,321 | $9,547 | 24.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 65 | 163 | $45,151 | $9,350 | 20.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 20 | 44 | $17,336 | $4,278 | 24.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 22 | 31 | $17,267 | $4,247 | 24.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 22 | 27 | $14,094 | $3,471 | 24.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 18 | 18 | $14,346 | $2,890 | 20.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 59 | 233 | $63,609 | $15,844 | 24.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 53 | 63 | $48,573 | $11,703 | 24.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 30 | 122 | $50,142 | $11,316 | 22.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 29 | 55 | $30,635 | $7,629 | 24.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 33 | 78 | $21,606 | $4,870 | 22.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 20 | 47 | $18,518 | $4,608 | 24.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 20 | 91 | $37,401 | $9,225 | 24.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 32 | 86 | $33,884 | $8,175 | 24.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 35 | 106 | $28,938 | $6,984 | 24.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 23 | 30 | $23,130 | $5,703 | 24.7% |
About Dr. Uqba Khan, M.D
Dr. Uqba Khan, M.D is a Hematology & Oncology healthcare provider based in Brooklyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/07/2013. The National Provider Identifier (NPI) number assigned to this provider is 1780923920.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Uqba Khan, M.D has received a total of $20,789 in payments from pharmaceutical and medical device companies, with $4,503 received in 2024. These payments were reported across 47 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($19,588).
As a Medicare-enrolled provider, Khan has provided services to 937 Medicare beneficiaries, totaling 2,293 services with total Medicare billing of $208,437. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Brooklyn, NY
- Active Since 02/07/2013
- Last Updated 02/06/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1780923920
Products in Payments
- LUTONIX (Device) $3,991
- Lutonix DCB (Device) $3,320
- IMJUDO (Biological) $2,809
- LUMAKRAS (Drug) $2,744
- IMFINZI (Biological) $1,763
- CALQUENCE (Drug) $124.98
- VELCADE (Drug) $96.25
- OPDIVO (Biological) $49.62
- SOMATULINE DEPOT (Drug) $44.62
- Vitrakvi (Drug) $33.40
- Venclexta (Drug) $28.05
- LORBRENA (Drug) $27.05
- ZYTIGA (Drug) $26.93
- Imbruvica (Drug) $25.33
- ZEJULA (Drug) $22.41
- VYXEOS (Drug) $20.22
- VERZENIO (Drug) $20.00
- Pomalyst (Drug) $19.74
- Stivarga (Drug) $19.50
- DARZALEX (Biological) $16.79
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Brooklyn
Perry Cook, M.d, M.D
Hematology & Oncology — Payments: $1.4M
Hematology & Oncology $1.4M
Yiwu Huang, Md, MD
Hematology & Oncology — Payments: $268,275
Hematology & Oncology $268,275
Dr. Ilya Blokh, M.d, M.D
Hematology & Oncology — Payments: $191,276
Hematology & Oncology $191,276
Songchuan Guo, M.d, M.D
Hematology & Oncology — Payments: $106,907
Hematology & Oncology $106,907
Yiqing Xu, Md, Phd, MD, PHD
Hematology & Oncology — Payments: $51,145
Hematology & Oncology $51,145
Dr. Azriel Hirschfeld, M.d, M.D
Hematology & Oncology — Payments: $48,699
Hematology & Oncology $48,699